Stay updated on Testing KRT-232 Combo with Decitabine & Venetoclax in AML Clinical Trial
Sign up to get notified when there's something new on the Testing KRT-232 Combo with Decitabine & Venetoclax in AML Clinical Trial page.

Latest updates to the Testing KRT-232 Combo with Decitabine & Venetoclax in AML Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe page footer's revision label changed from v3.6.5 to v3.6.6, signaling a backend/template update rather than a content change.SummaryDifference0.0%

- Check15 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedThe page now shows a new release revision label (v3.6.5), indicating a minor platform update. This update does not change the study information or other critical content presented to users.SummaryDifference0.0%

- Check44 days agoChange DetectedThe page shows a new Revision: v3.6.4 label replacing the previous v3.6.3, indicating a backend platform update rather than a change to the study information.SummaryDifference0.0%

- Check65 days agoChange DetectedThe page revision label changed from v3.6.2 to v3.6.3, indicating a small version update to the page. No substantive content or data on the study details was altered.SummaryDifference0.0%

- Check72 days agoChange DetectedThe revision label in the page footer was updated from v3.6.0 to v3.6.2, indicating a software revision.SummaryDifference0.0%

- Check87 days agoChange DetectedAdded new help sections ('How to Read a Study Record', 'Common Questions', 'How to Join a Study') and updated navigation labels (Intervention/Treatment). Recruitment status now indicates no participants are being sought, and a revision tag (Revision: v3.6.0) was added.SummaryDifference1.0%

Stay in the know with updates to Testing KRT-232 Combo with Decitabine & Venetoclax in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Testing KRT-232 Combo with Decitabine & Venetoclax in AML Clinical Trial page.